In the News


mutaFISH™ probes utilized for in situ mutation detection in circulating tumor cells


2017/05/05


Neihu, Taiwan (May 05, 2017)





About Abnova


Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products and services relating circulating rare cell, circulating exosome, and circulating cell-free RNA for early to metastatic and recurrent disease and treatment diagnosis, guidance, prediction, and monitoring. Abnova facility is ISO13485 and GMP certified for bioreagent and automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)


Back

©2020 Wellconn Genomics 懷慷醫事檢驗所. All rights reserved.